Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1980 Feb;43(2):171–174. doi: 10.1136/jnnp.43.2.171

Fluvoxamine and clomipramine in the treatment of cataplexy.

M Schachter, J D Parkes
PMCID: PMC490494  PMID: 6766990

Abstract

Fluvoxamine 25-200 mg daily and clomipramine 25-200 mg daily were given for separate three week periods to 18 subjects with narcolepsy and cataplexy. Both drugs improved cataplexy but not narcolepsy. Fluvoxamine was less active than clomipramine, but both drugs abolished cataplexy in individual subjects. Gastrointestinal side effects prevented treatment with fluvoxamine in five subjects. All patients completed the clomipramine phase of the trial, but two men complained of delayed ejaculation. Fluvoxamine is a more potent inhibitor of 5-hydroxytryptamine (5-HT) reuptake in some systems, but not in others. It is therefore uncertain whether the greater anticataplectic effect of clomipramine is due to a greater inhibition of 5-HT reuptake or to other mechanisms.

Full text

PDF
171

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRODIE B., DICK P., KIELHOLZ P., POELDINGER W., THEOBALD W. Preliminary pharmacological and clinical results with desmethylimipramine (DMI) G 35020, a metabolite of imipramine. Psychopharmacologia. 1961 Dec 19;2:467–474. doi: 10.1007/BF00407446. [DOI] [PubMed] [Google Scholar]
  2. Claassen V., Davies J. E., Hertting G., Placheta P. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol. 1977 Aug;60(4):505–516. doi: 10.1111/j.1476-5381.1977.tb07528.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Guilleminault C., Raynal D., Takahashi S., Carskadon M., Dement W. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand. 1976 Jul;54(1):71–87. doi: 10.1111/j.1600-0404.1976.tb07621.x. [DOI] [PubMed] [Google Scholar]
  4. Guilleminault C., Wilson R. A., Dement W. C. A study on cataplexy. Arch Neurol. 1974 Oct;31(4):255–261. doi: 10.1001/archneur.1974.00490400069008. [DOI] [PubMed] [Google Scholar]
  5. Hishikawa Y., Ida H., Nakai K., Kaneko Z. Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran). J Neurol Sci. 1966 Sep-Oct;3(5):453–461. doi: 10.1016/0022-510x(66)90001-3. [DOI] [PubMed] [Google Scholar]
  6. Jones R. B., Luscombe D. K. Single dose studies with clomipramine in normal subjects. Postgrad Med J. 1976;52(3 Suppl):62–68. [PubMed] [Google Scholar]
  7. Passouant P., Baldy-Moulinier M., Aussilloux C. Etat de mal cataplectique au cours d'une maladie de Gélineau; influence de la clomipramine. Rev Neurol (Paris) 1970 Jul;123(1):56–60. [PubMed] [Google Scholar]
  8. Schmidt H. S., Clark R. W., Hyman P. R. Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. Am J Psychiatry. 1977 Feb;134(2):183–185. doi: 10.1176/ajp.134.2.183. [DOI] [PubMed] [Google Scholar]
  9. Shapiro W. R. Treatment of Cataplexy with Clomipramine. Arch Neurol. 1975 Oct;32(10):653–656. doi: 10.1001/archneur.1975.00490520023002. [DOI] [PubMed] [Google Scholar]
  10. Sinclair J. G., Sastry B. S. The blockade of bulbospinal inhibition by imipramine, desipramine and pargyline. Neuropharmacology. 1974 Jul;13(7):643–650. doi: 10.1016/0028-3908(74)90054-9. [DOI] [PubMed] [Google Scholar]
  11. Wyatt R. J. The serotonin-catecholamine-dream bicycle: a clinical study. Biol Psychiatry. 1972 Aug;5(1):33–64. [PubMed] [Google Scholar]
  12. YOSS R. E., DALY D. D. Narcolepsy. Med Clin North Am. 1960 Jul;44:953–968. doi: 10.1016/s0025-7125(16)33982-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES